RNase non-sensitive and endocytosis independent siRNA delivery system: delivery of siRNA into tumor cells and high efficiency induction of apoptosis
Source abstract
Abstract
To date, RNase degradation and endosome/lysosome trapping are still serious problems for siRNA-based molecular therapy, although different kinds of delivery formulations have been tried. In this report, a cell penetrating peptide (CPP, including a positively charged segment, a linear segment, and a hydrophobic segment) and a single wall carbon nanotube (SWCNT) are applied together by a simple method to act as a siRNA delivery system. The siRNAs first form a complex with the positively charged segment of CPP via electrostatic forces, and the siRNA-CPP further coats the surface of the SWCNT via hydrophobic interactions. This siRNA delivery system is non-sensitive to RNase and can avoid endosome/lysosome trapping in vitro. When this siRNA delivery system is studied in Hela cells, siRNA uptake was observed in 98% Hela cells, and over 70% mRNA of mammalian target of rapamycin (mTOR) is knocked down, triggering cell apoptosis on a significant scale. Our siRNA delivery system is easy to handle and benign to cultured cells, providing a very efficient approach for the delivery of siRNA into the cell cytosol and cleaving the target mRNA therein.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Virus-based gene therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (33)
Show source-provided references
1. Nakao · Oncol. Rep. · 2006 · 16 · 38910.3727/000000006783980919 ↗
2. Gao · Acta Pharmacol. Sin. · 2005 · 26 · 37710.1111/j.1745-7254.2005.00053.x ↗
3. Uchida · Mol. Ther. · 2004 · 10 · 16210.1016/j.ymthe.2004.05.006 ↗
4. Faltus · Neoplasia · 2004 · 6 · 78610.1593/neo.04313 ↗
5. Crnkovic-Mertens · Oncogene · 2003 · 22 · 833010.1038/sj.onc.1206973 ↗
6. Shi · Expert Opin. Biol. Ther. · 2011 · 11 · 510.1517/14712598.2010.532483 ↗
7. Pento · Drugs Future · 2007 · 32 · 106110.1358/dof.2007.032.12.1143490 ↗
8. Oh · Adv. Drug Delivery Rev. · 2009 · 61 · 85010.1016/j.addr.2009.04.018 ↗
9. Dominska · J. Cell Sci. · 2010 · 123 · 118310.1242/jcs.066399 ↗
10. Juliano · Mol. Pharmaceutics · 2009 · 6 · 68610.1021/mp900093r ↗
11. Shutao · J. Nanomater. · 2011 · 742895
12. Xia · ACS Nano · 2009 · 3 · 327310.1021/nn900918w ↗
13. Li · Biomaterials · 2011 · 32 · 954610.1016/j.biomaterials.2011.08.068 ↗
14. Hom · Small · 2010 · 6 · 118510.1002/smll.200901966 ↗
15. Lee · Small · 2011 · 7 · 36410.1002/smll.201001314 ↗
16. Guo · ACS Nano · 2010 · 4 · 550510.1021/nn101638u ↗
17. Elbakry · Nano Lett. · 2009 · 9 · 205910.1021/nl9003865 ↗
18. Dong · Prog. Biochem. Biophys. · 2012 · 39 · 39610.3724/SP.J.1206.2012.00190 ↗
19. Zhang · J. Controlled Release · 2007 · 123 · 110.1016/j.jconrel.2007.07.016 ↗
20. de Martimprey · Eur. J. Pharm. Biopharm. · 2009 · 71 · 49010.1016/j.ejpb.2008.09.024 ↗
21. Varkouhi · Int. J. Pharm. · 2011 · 416 · 41910.1016/j.ijpharm.2011.02.009 ↗
22. Singh · J. Mater. Chem. · 2011 · 21 · 485010.1039/c0jm04064a ↗
23. Kam · J. Am. Chem. Soc. · 2005 · 127 · 1249210.1021/ja053962k ↗
24. Liu · Angew. Chem., Int. Ed. · 2007 · 46 · 202310.1002/anie.200604295 ↗
25. Baldo · Curr. Cancer Drug Targets · 2008 · 8 · 64710.2174/156800908786733513 ↗
26. Easton · Oncogene · 2006 · 25 · 643610.1038/sj.onc.1209886 ↗
27. Huang · Curr. Opin. Pharmacol. · 2003 · 3 · 37110.1016/S1471-4892(03)00071-7 ↗
28. Meric-Bernstam · J. Clin. Oncol. · 2009 · 27 · 227810.1200/JCO.2008.20.0766 ↗
29. Petroulakis · Br. J. Cancer · 2006 · 94 · 19510.1038/sj.bjc.6602902 ↗
30. Sparks · Oncogene · 2010 · 29 · 373310.1038/onc.2010.139 ↗
31. Yuan · J. Hematol. Oncol. · 2009 · 2 · 4510.1186/1756-8722-2-45 ↗
32. Wu · ACS Nano · 2008 · 2 · 202310.1021/nn800325a ↗
33. Kostarelos · Nat. Nanotechnol. · 2007 · 2 · 10810.1038/nnano.2006.209 ↗